• Media Centre
  • Investor relations
  • Client area
  • Client area
  • Stewardship policy
  • Annual reports service

Form of Proxy

REGENERON PHARMACEUTICALS, INC.

Notes

No. Proposition For Against Abstain
1

Election of Director: Bonnie L. Bassler, Ph.D.

2

Election of Director: Michael S. Brown, M.D.

3

Election of Director: Leonard S. Schleifer, M.D., Ph.D.

4

Election of Director: George D. Yancopoulos, M.D., Ph.D.

5

Ratification of the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2025.

6

Proposal to approve, on an advisory basis, executive compensation.

7

Proposal to approve an amendment to the Companys Certificate of Incorporation to declassify the board of directors.

8

Proposal to approve an amendment to Article IV, Section 2(e)(8) of the Certificate of Incorporation.

9

Proposal to approve an amendment to Article VI of the Certificate of Incorporation.